Actively Recruiting
Evaluating B007 Treatment Compared to Placebo in Adults With Generalized Myasthenia Gravis A Randomized, Double-Blind, Multicenter Study
Led by Shanghai Jiaolian Drug Research and Development Co., Ltd · Updated on 2026-08-14
104
Participants Needed
18
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of B007 in adults with generalized myasthenia gravis, a condition characterized by muscle weakness. This randomized, double-blind, placebo-controlled trial is sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd and aims to better understand how B007 may impact the daily activities affected by this condition. Participants will receive either B007 or a matching placebo through subcutaneous injections on days 1 and 15. The study includes different dose levels of B007 and compares outcomes over approximately 16 weeks for the primary measure, with additional assessments extending to about 24 weeks and safety monitoring for up to one year. Throughout the trial, participants will be monitored for changes in their myasthenia gravis symptoms using specific scales such as MG-ADL, QMG, MGQoL15r, and MGC. Researchers will also track any treatment-emergent adverse events. Participants are expected to maintain stable doses of their standard care treatments during the study, and the trial will last until the end of 2026, including follow-up periods for comprehensive safety and efficacy assessments.
CONDITIONS
Brief Title
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Research Team
J
Jianying Xi
H
Huan Yang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here